The FDA granted fast track status to TRC105 for the treatment of metastatic renal cell carcinoma, according to a press release from the drug’s manufacturer.TRC105 (Tracon) is intended for patients with metastatic renal cell carcinoma who experienced disease progression following treatment with a VEGF inhibitor in combination with standard-dose axitinib (Inlyta, Pfizer).
No comments:
Post a Comment